Single ventricle heart disease, a congenital anomaly affecting approximately 6 in every 10,000 infants born annually in the United States, presents a formidable challenge for modern medicine. These patients are born with a heart defect such that only one ventricle can effectively pump blood, necessitating the Fontan surgical procedure to create a unique circulatory pathway. While this surgery is lifesaving, it introduces a precarious physiological state where systemic venous blood passively flows to the pulmonary arteries without the pumping action from a right ventricle, imposing chronic systemic circulation limitations and organ strain.

Despite the critical importance of the Fontan procedure in survival, the long-term repercussions are profound and pervasive. Patients with Fontan circulation typically endure significant stress not only on their cardiovascular system but also on other vital organ systems including the liver, kidneys, and lungs. This cumulative organ dysfunction is driven by pressure and flow abnormalities inherent in the altered circulatory physiology, leading to progressive complications such as Fontan-associated liver disease, protein-losing enteropathy, and plastic bronchitis, among others.

Current clinical protocols for surveillance and management of patients living with Fontan physiology remain suboptimal. A foundational challenge lies in the inability to detect early signals of decline through existing monitoring techniques, which often results in patients progressing silently towards acute, life-threatening complications. Medical practitioners frequently encounter difficulties in prognosticating disease trajectory and timing optimal interventions, underscoring an urgent need for innovative diagnostic tools and biomarkers.

The program conceived by the AHA and Additional Ventures aims to bridge this critical gap by fostering a coordinated, multidisciplinary approach combining clinical expertise, patient-centered insights, and cutting-edge research. Leveraging the AHA’s expansive research infrastructure, guideline development capabilities, and data coordination mechanisms, alongside Additional Ventures’ deep scientific acumen and strategic philanthropy focused exclusively on single ventricle heart disease, the partnership sets the stage for transformative outcomes.

One of the principal objectives centers on the creation of novel predictive models and monitoring tools that can accurately identify early pathophysiological changes in Fontan circulation patients. This entails integrating advanced imaging modalities, hemodynamic assessments, biomarker discovery, and machine learning algorithms to decipher the complex interplay of cardiovascular and systemic alterations. By harnessing big data analytics and longitudinal patient registries, the initiative aspires to generate robust, personalized risk stratification frameworks.

Additionally, the initiative emphasizes active engagement with patients and caregivers to incorporate lived experiences into research and care pathways. This patient-centered approach acknowledges the heterogeneity of disease manifestation and progression, fostering tailored treatment modalities that reflect individual needs and quality of life considerations. The inclusion of patient voices will be paramount in shaping clinical guidelines and determining meaningful endpoints for therapeutic interventions.

From a scientific standpoint, the collaborative program will explore mechanistic underpinnings of multiorgan dysfunction caused by Fontan physiology. Investigations into the molecular and cellular pathways affected by chronic low cardiac output and venous hypertension are anticipated to reveal novel therapeutic targets. The exploration of fibrosis pathways in liver and lung tissue, renal impairment biomarkers, and inflammatory cascades could pave the way for targeted pharmacologic therapies aimed at mitigating organ damage.

Moreover, a critical aspect of this undertaking is the establishment of an integrated infrastructure to support ongoing research and clinical trials. This includes enhancing existing registries, standardizing data collection methods across institutions, and promoting collaborative networks among cardiologists, hepatologists, pulmonologists, nephrologists, and researchers. The vision is to create a sustainable ecosystem that encourages translational research from bench to bedside, accelerating scientific discoveries into clinical practice.

The six-year timeline for the project is designed to encompass iterative phases, starting with comprehensive assessments of current care paradigms and identification of knowledge voids. Subsequent stages focus on pilot studies to validate innovative diagnostic methodologies, followed by multi-center clinical validation and eventual dissemination of evidence-based guidelines. This phased approach ensures adaptive learning and responsiveness to emerging scientific insights over the duration of the project.

The implications of successfully improving the predictive and preventative care of Fontan circulation patients cannot be overstated. Enhanced surveillance and early intervention have the potential to significantly reduce morbidity and mortality, improve functional capacity, and extend life expectancy. Furthermore, the model generated from this initiative could serve as a blueprint for tackling other complex congenital and chronic cardiovascular diseases that similarly suffer from fragmented care and limited prognostic tools.

Historically, the Fontan procedure marked a paradigm shift by enabling survival of patients who would otherwise face early mortality. However, decades later, the medical community confronts the unintended consequences of this complex physiology. This new initiative underscores a shift from life preservation towards life optimization — transforming reactive management into proactive, precision healthcare tailored to this vulnerable population.

According to Mariell Jessup, the AHA’s chief medical and science officer, the coordinated efforts aim not only to deepen scientific understanding but also to deliver actionable clinical insights that can improve patient outcomes through timely intervention. Similarly, Kirstie Keller, CEO of Additional Ventures, emphasizes the importance of collaboration across the scientific and clinical spectrum to unlock novel solutions and enable a future where lifelong care for Fontan patients is informed by rigorous science and comprehensive monitoring.

In summary, this unprecedented partnership between the American Heart Association and Additional Ventures embodies an essential strategic investment targeting an underserved population afflicted with a rare but devastating congenital heart defect. By mobilizing resources, expertise, and patient engagement, the program charts a bold course to overcome existing barriers, ushering in a new era of innovation that promises to fundamentally alter the prognosis for individuals with Fontan circulation.

The collaborative framework envisaged not only aspires to catalyze immediate improvements in clinical care but also to sow seeds for future research breakthroughs that may ultimately approach curative strategies for single ventricle heart disease. As such, it stands as a testament to the power of focused multidisciplinary collaboration in tackling some of the most formidable challenges posed by congenital cardiovascular disorders.

Subject of Research: Single Ventricle Heart Disease and Fontan Circulation: Advancing Predictive and Preventive Care Strategies

Article Title: American Heart Association and Additional Ventures Launch $20 Million Initiative to Revolutionize Care for Fontan Circulation Patients

News Publication Date: March 30, 2026

Web References:

• American Heart Association on Single Ventricle Defects: https://www.heart.org/en/health-topics/congenital-heart-defects/about-congenital-heart-defects/single-ventricle-defects
• Additional Ventures Website: https://additionalventures.org
• Additional Ventures 2025 Impact Report: https://www.additionalventures.org/wp-content/uploads/2026/03/Additional-Ventures-Impact-Report-2025-FINAL-260317.pdf

References:
[1] Single Ventricle Heart Disease Incidence – ScienceDirect Article: https://www.sciencedirect.com/science/article/abs/pii/S1058981302000425

Keywords: Fontan procedure, single ventricle heart disease, congenital heart defects, cardiovascular disorders, predictive health monitoring, multidisciplinary care, organ dysfunction, imaging biomarkers, patient-centered research

Endothelial cells are pivotal in maintaining vascular homeostasis. They regulate various physiological processes, including vasodilation, inflammation, and thrombosis. In patients with Fontan circulation, there is a marked tendency towards endothelial dysfunction, characterized by impaired nitric oxide production and an imbalance between pro- and anti-inflammatory factors. This condition not only influences hemodynamic stability but also fosters the development of chronic complications, making the understanding of this dysfunction paramount.

The pathophysiology of endothelial dysfunction in Fontan circulation appears to stem from several interrelated mechanisms. First and foremost, the theory of decreased shear stress is critical. In a normally functioning cardiovascular system, blood flow exerts shear stress on the endothelium, stimulating the release of substances crucial for vascular health. However, in the Fontan circulation, altered hemodynamics result in diminished shear stress, which may contribute to the impaired function of endothelial cells and thus promote dysfunction.

Another essential element in this discourse is the role of inflammation. Chronic inflammation is a well-documented consequence of endothelial dysfunction. In patients with Fontan circulation, there is an increase in circulating inflammatory markers, which correlates with the severity of endothelial impairment. This inflammatory milieu may result from the hemodynamic changes associated with the Fontan procedure, leading to a vicious cycle of endothelial injury and dysfunction that exacerbates cardiac and systemic complications.

Moreover, the role of oxidative stress cannot be overstated. Endothelial cells produce reactive oxygen species (ROS) as a response to various stimuli. In patients with Fontan circulation, the excessive generation of ROS can overwhelm the oxidative stress defense mechanisms, leading to cellular damage and functional impairment. This oxidative imbalance likely contributes to the pathophysiological changes observed in the endothelium, reinforcing the need for targeted therapeutic strategies aimed at reducing oxidative stress and improving endothelial function.

The implications of endothelial dysfunction on clinical outcomes are profound. Patients with compromised endothelial function post-Fontan procedure may experience various adverse events, including thromboembolic complications, arrhythmias, and heart failure. The correlation between abnormal endothelial function and cardiovascular morbidity underscores the necessity of careful monitoring of these patients. Timely interventions based on endothelial health may enhance quality of life and longevity in this unique patient population.

Research has pushed forward the notion that rehabilitation of endothelial function could be a viable mechanism for improving the prognosis of Fontan patients. Strategies including lifestyle modifications, pharmacological interventions, and advancements in surgical techniques need further exploration to foster better endothelial health and overall outcomes. Notably, endothelial function can be a target for novel therapeutic approaches, potentially offering hope to those afflicted by the sequelae of the Fontan procedure.

The concept of ‘bench to bedside’ has become more relevant than ever, as the understanding gained from basic science can be directly applicable to clinical practice. Innovations in biochemistry and molecular biology may lead to the identification of biomarkers for endothelial dysfunction, providing a critical tool for clinicians aiming to monitor disease progression and tailor therapy accordingly. This paradigm shift emphasizes the importance of translational research, where scientific discoveries can translate into tangible improvements in patient care.

In a parallel development, the investigation of lifestyle factors, including diet and exercise, presents an exciting opportunity to bolster endothelial function in patients with Fontan circulation. Interventions targeting modifiable risk factors may lead to better outcomes and increased life expectancy. Understanding the role of physical activity in mitigating endothelial dysfunction could pave the way for comprehensive care strategies that integrate medical therapy with lifestyle modifications.

As we delve deeper into the realm of endothelial dysfunction in Fontan circulation, the need for multidisciplinary collaboration is evident. By fostering partnerships between cardiologists, researchers, and allied health professionals, we can develop holistic care strategies that address the multifaceted challenges of managing this complex patient group. Collaborative efforts may lead to innovations in patient education and access to cutting-edge therapies that can significantly impact clinical management.

The future of research in this area holds promise. With ongoing advancements in genetic and proteomic technologies, we may soon uncover the intricate pathways that lead to endothelial dysfunction in Fontan patients. Enhanced understanding at the molecular level will undoubtedly contribute to the development of target-specific therapies that could revolutionize the management of these complex cases.

In conclusion, the exploration of endothelial dysfunction in Fontan circulation is a critical area of investigation that warrants continued focus. The pathophysiology underlying this phenomenon is intricate, involving reduced shear stress, chronic inflammation, and oxidative stress. Understanding these mechanisms is paramount for devising effective interventions that can improve patient outcomes. As researchers and clinicians work collaboratively to bridge the gap between laboratory findings and clinical application, we may soon witness a transformation in the management of endothelial dysfunction, offering hope to a cohort of patients previously facing daunting challenges.

Research outcomes emphasize the importance of targeted studies aimed at addressing the issues of endothelial dysfunction in Fontan patients. Future research endeavors will need to refine our understanding of the nuances of endothelial biology in this unique patient population, leading to innovative therapeutic avenues that enhance cardiovascular health and improve survival.

As we reflect on the significant advancements made in our understanding of the Fontan circulation, it is imperative to remain cognizant of the ongoing challenges that patients face. By remaining committed to research and interdisciplinary collaboration, we stand on the brink of groundbreaking discoveries that can profoundly enhance the quality of life for those affected by congenital heart disease.

Subject of Research: Endothelial Dysfunction in Fontan Circulation

Article Title: Pathophysiology of endothelial dysfunction in Fontan circulation: from bench to bedside and back again

Article References:

Baroutidou, A., Karagiannidis, A.G., Dimitroulas, T. et al. Pathophysiology of endothelial dysfunction in Fontan circulation: from bench to bedside and back again. Angiogenesis 28, 45 (2025). https://doi.org/10.1007/s10456-025-09996-2

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10456-025-09996-2

Keywords: Endothelial dysfunction, Fontan procedure, cardiovascular health, hemodynamics, inflammation, oxidative stress, clinical outcomes, therapeutic strategies.